{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:29:59Z","timestamp":1791188999710,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":73,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642012211","type":"print"},{"value":"9783642012228","type":"electronic"}],"license":[{"start":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010]]},"DOI":"10.1007\/978-3-642-01222-8_1","type":"book-chapter","created":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T09:21:41Z","timestamp":1257499301000},"page":"3-20","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Imatinib Mesylate"],"prefix":"10.1007","author":[{"given":"Cornelius F.","family":"Waller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"key":"1_CR1_1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/0014-5793(93)80884-W","volume":"330","author":"M Anafi","year":"1993","unstructured":"Anafi M, Gazit A, Gilon C, Neriah YB, Levitzki A (1993a) Tyrphostin-induced differentiation of mouse erythroleukemia cells. FEBS Lett 330: 260\u2013264","journal-title":"FEBS Lett"},{"key":"1_CR2_1","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1182\/blood.V82.12.3524.3524","volume":"82","author":"M Anafi","year":"1993","unstructured":"Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A (1993b) Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 82:3524\u20133529","journal-title":"Blood"},{"key":"1_CR3_1","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","volume":"104","author":"M Baccarani","year":"2004","unstructured":"Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D et al (2004) Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104:4245\u20134251","journal-title":"Blood"},{"key":"1_CR4_1","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809\u20131820","journal-title":"Blood"},{"key":"1_CR5_1","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1046\/j.1365-2133.1996.d01-1092.x","volume":"135","author":"RL Barnhill","year":"1996","unstructured":"Barnhill RL, Xiao M, Graves D, Antoniades HN (1996) Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br J Dermatol 135:898\u2013904","journal-title":"Br J Dermatol"},{"key":"1_CR6_1","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26: 626\u2013632","journal-title":"J Clin Oncol"},{"key":"1_CR7_1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"key":"1_CR8_1","first-page":"11","volume":"1551","author":"E Buchdunger","year":"2001","unstructured":"Buchdunger E, Matter A, Druker BJ (2001) Bcr-Abl inhibition as a modality of CML therapeutics. Biochim Biophys Acta 1551:M11\u2013M18","journal-title":"Biochim Biophys Acta"},{"key":"1_CR9_1","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100\u2013104","journal-title":"Cancer Res"},{"key":"1_CR10_1","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1073\/pnas.92.7.2558","volume":"92","author":"E Buchdunger","year":"1995","unstructured":"Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon NB (1995) Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A 92:2558\u20132562","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR11_1","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1182\/blood.V93.11.3973","volume":"93","author":"C Carlo-Stella","year":"1999","unstructured":"Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, Savoldo B, Cilloni D, Tabilio A, Levitzki A, Rizzoli V (1999) Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. Blood 93: 3973\u20133982","journal-title":"Blood"},{"issue":"2","key":"1_CR12_1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1634\/theoncologist.2008-0255","volume":"14","author":"MH Cohen","year":"2009","unstructured":"Cohen MH, Farrell A, Justice R, Pazdur R (2009) Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and\/or Unresectable Malignant Gastrointestinal Stromal Tumors. Oncologist 14(2):174\u2013180","journal-title":"Oncologist"},{"key":"1_CR13_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.12.11.1","volume":"11","author":"MH Cohen","year":"2005","unstructured":"Cohen MH, Johnson JR, Pazdur R (2005) U.S. food and drug administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 11:12\u201319","journal-title":"Clin Cancer Res"},{"key":"1_CR14_1","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935\u2013942","journal-title":"Clin Cancer Res"},{"key":"1_CR15_1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","volume":"102","author":"J Cortes","year":"2003","unstructured":"Cortes J, Giles F, O\u2019Brien S, Thomas D, Garcia-Manero G, Rios MB, Faderl S, Verstovsek S, Ferrajoli A, Freireich EJ et al (2003) Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 102:83\u201386","journal-title":"Blood"},{"key":"1_CR16_1","first-page":"3034","volume":"8","author":"R Dagher","year":"2002","unstructured":"Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R (2002) Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034\u20133038","journal-title":"Clin Cancer Res"},{"key":"1_CR17_1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 247:824\u2013830","journal-title":"Science"},{"key":"1_CR18_1","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640\u20132653","journal-title":"Blood"},{"key":"1_CR19_1","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","volume":"90","author":"MW Deininger","year":"1997","unstructured":"Deininger MW, Goldman JM, Lydon N, Melo JV (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691\u20133698","journal-title":"Blood"},{"key":"1_CR20_1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343\u20133356","journal-title":"Blood"},{"issue":"Suppl 5","key":"1_CR21_1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0959-8049(02)80603-7","volume":"38","author":"GD Demetri","year":"2002","unstructured":"Demetri GD (2002) Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 38(Suppl 5):S52\u2013S59","journal-title":"Eur J Cancer"},{"key":"1_CR22_1","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472\u2013480","journal-title":"N Engl J Med"},{"key":"1_CR23_1","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ (2008) Translation of the Philadelphia chromosome into therapy for CML. Blood 112:4808\u20134817","journal-title":"Blood"},{"key":"1_CR24_1","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"1_CR25_1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI9083","volume":"105","author":"BJ Druker","year":"2000","unstructured":"Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3\u20137","journal-title":"J Clin Invest"},{"key":"1_CR26_1","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038\u20131042","journal-title":"N Engl J Med"},{"key":"1_CR27_1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"1_CR28_1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561\u2013566","journal-title":"Nat Med"},{"key":"1_CR29_1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1006\/bcmd.1997.0155","volume":"23","author":"C Gambacorti-Passerini","year":"1997","unstructured":"Gambacorti-Passerini C, Le Coutre P, Mologni L, Fanelli M, Bertazolli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB (1997) Inhibition of the ABL kinase activity blocks the proliferation of BCR\/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380\u2013394","journal-title":"Blood Cells Mol Dis"},{"key":"1_CR30_1","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/blood-2003-04-1010","volume":"102","author":"M Gardembas","year":"2003","unstructured":"Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N et al (2003) Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 102:4298\u20134305","journal-title":"Blood"},{"key":"1_CR31_1","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"1_CR32_1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","volume":"352","author":"A Gratwohl","year":"1998","unstructured":"Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D et al (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic leukemia working party of the European group for blood and marrow transplantation. Lancet 352:1087\u20131092","journal-title":"Lancet"},{"key":"1_CR33_1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/ijc.1190","volume":"92","author":"A Greco","year":"2001","unstructured":"Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA (2001) Growth-inhibitory effect of STI571 on cells transformed by the COL1A1\/PDGFB rearrangement. Int J Cancer 92:354\u2013360","journal-title":"Int J Cancer"},{"key":"1_CR34_1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1634\/theoncologist.9-3-271","volume":"9","author":"F Guilhot","year":"2004","unstructured":"Guilhot F (2004) Indications for imatinib mesylate therapy and clinical management. Oncologist 9:271\u2013281","journal-title":"Oncologist"},{"key":"1_CR35_1","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O\u2019Brien SG, Dobrez DG, Hensley ML, Cella D (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21:2138\u20132146","journal-title":"J Clin Oncol"},{"key":"1_CR36_1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nm0107-13a","volume":"13","author":"A Hatfield","year":"2007","unstructured":"Hatfield A, Owen S, Pilot PR (2007) In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019 [letter]. Nat Med 13:13","journal-title":"Nat Med"},{"key":"1_CR37_1","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","volume":"109","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A et al (2007a) Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 109:4686\u20134692","journal-title":"Blood"},{"key":"1_CR38_1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M (2007b) Chronic myeloid leukaemia. Lancet 370:342\u2013350","journal-title":"Lancet"},{"key":"1_CR39_1","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.20.6.1692","volume":"20","author":"MC Heinrich","year":"2002","unstructured":"Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692\u20131703","journal-title":"J Clin Oncol"},{"key":"1_CR40_1","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342\u20134349","journal-title":"J Clin Oncol"},{"key":"1_CR41_1","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C et al (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26: 5360\u20135367","journal-title":"J Clin Oncol"},{"key":"1_CR42_1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/344251a0","volume":"344","author":"N Heisterkamp","year":"1990","unstructured":"Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in bcr\/abl transgenic mice. Nature 344:251\u2013253","journal-title":"Nature"},{"key":"1_CR43_1","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","volume":"111","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J et al (2008) Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111:1039\u20131043","journal-title":"Blood"},{"key":"1_CR44_1","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423\u20131432","journal-title":"N Engl J Med"},{"key":"1_CR45_1","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","volume":"109","author":"JV Jovanovic","year":"2007","unstructured":"Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A et al (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109:4635\u20134640","journal-title":"Blood"},{"key":"1_CR46_1","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645\u2013652","journal-title":"N Engl J Med"},{"key":"1_CR47_1","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkel\u00e4","year":"2006","unstructured":"Kerkel\u00e4 R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine 12:908\u2013916","journal-title":"Nature Medicine"},{"key":"1_CR48_1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","volume":"37","author":"JB Konopka","year":"1984","unstructured":"Konopka JB, Watanabe SM, Witte ON (1984) An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035\u20131042","journal-title":"Cell"},{"key":"1_CR49_1","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O\u2019Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022\u20134028","journal-title":"Blood"},{"key":"1_CR50_1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","volume":"92","author":"P le Coutre","year":"1999","unstructured":"le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti- Passerini C (1999) In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 92:163\u2013168","journal-title":"J Natl Cancer Inst"},{"key":"1_CR51_1","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1126\/science.7892601","volume":"267","author":"A Levitzky","year":"1995","unstructured":"Levitzky A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782\u20131788","journal-title":"Science"},{"key":"1_CR52_1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079\u20131082","journal-title":"Science"},{"key":"1_CR53_1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9440(10)64946-2","volume":"156","author":"ML Lux","year":"2000","unstructured":"Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri GD, Xiao S, Singer S, Fletcher CD, Fletcher JA (2000) Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 156:791\u2013795","journal-title":"Am J Pathol"},{"key":"1_CR54_1","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2165\/00003495-200161120-00007","volume":"61","author":"K Lyseng-Williamson","year":"2001","unstructured":"Lyseng-Williamson K, Jarvis B (2001) Imatinib. Drugs 61:1765\u20131774","journal-title":"Drugs"},{"key":"1_CR55_1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00280-008-0764-0","volume":"63","author":"E Marangon","year":"2009","unstructured":"Marangon E, Citterio M, Sala F, Barisone E, Lippi AA, Rizzari C, Biondi A, D\u2019Incalci M, Zucchetti M (2009) Pharmacokinetic profile of imatinib mesylate and N-demethyl-imatinib (CGP74588) in children with newly diagnosed Ph+ acute leukemias. Cancer Chemother Pharmacol 63: 563\u2013566","journal-title":"Cancer Chemother Pharmacol"},{"key":"1_CR56_1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1200\/JCO.20.1.325","volume":"20","author":"MJ Mauro","year":"2002","unstructured":"Mauro MJ, O\u2019Dwyer M, Heinrich MC, Druker BJ (2002) STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 20:325\u2013334","journal-title":"J Clin Oncol"},{"key":"1_CR57_1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/138161209787002933","volume":"15","author":"BA Mueller","year":"2009","unstructured":"Mueller BA (2009) Imatinib and its successors \u2013 how modern chemistry has changed drug development. Curr Pharm Design 15:120\u2013133","journal-title":"Curr Pharm Design"},{"key":"1_CR58_1","unstructured":"NCCN_Practice_Guidelines_in_Oncology (- v.3.2008. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/cml.pdf)"},{"key":"1_CR59_1","first-page":"1497","volume":"132","author":"PC Nowell","year":"1960","unstructured":"Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497","journal-title":"Science"},{"key":"1_CR60_1","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994\u20131004","journal-title":"N Engl J Med"},{"key":"1_CR61_1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood.V112.11.76.76","volume":"112","author":"SG O\u2019Brien","year":"2008","unstructured":"O\u2019Brien SG, Guilhot F, Goldman J, Hochhaus A, Hughes T, Radich J, Rudoltz M, Filian J, Gathmann I, Druker B et al (2008) International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 112:76","journal-title":"Blood"},{"key":"1_CR62_1","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1182\/blood.V97.8.2440","volume":"97","author":"K Okuda","year":"2001","unstructured":"Okuda K, Weisberg E, Gilliland DG, Griffin JD (2001) ARG tyrosine kinase activity is inhibited by STI571. Blood 97:2440\u20132448","journal-title":"Blood"},{"key":"1_CR63_1","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA et al (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965\u20131971","journal-title":"Blood"},{"key":"1_CR64_1","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood-2004-01-0246","volume":"104","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Tefferi A (2004) Imatinib targets other than bcr\/abl and their clinical relevance in myeloid disorders. Blood 104:1931\u20131939","journal-title":"Blood"},{"key":"1_CR65_1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293","journal-title":"Nature"},{"key":"1_CR66_1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330\u20131340","journal-title":"N Engl J Med"},{"key":"1_CR67_1","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530\u20133539","journal-title":"Blood"},{"key":"1_CR68_1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1056\/NEJMct071828","volume":"357","author":"CA Schiffer","year":"2007","unstructured":"Schiffer CA (2007) BCR-ABL tyrosine kinase inhibitors in chronic myelogenous leukemia. N Engl J Med 357:258\u2013265","journal-title":"N Engl J Med"},{"key":"1_CR69_1","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A et al (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26: 3204\u20133212","journal-title":"J Clin Oncol"},{"key":"1_CR70_1","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","volume":"22","author":"NP Shah","year":"2003","unstructured":"Shah NP, Sawyers CL (2003) Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22:7389\u20137395","journal-title":"Oncogene"},{"key":"1_CR71_1","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL et al (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928\u20131937","journal-title":"Blood"},{"key":"1_CR72_1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.leu.2402889","volume":"17","author":"N von Bubnoff","year":"2003","unstructured":"von Bubnoff N, Peschel C, Duyster J (2003) Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 17:829\u2013838","journal-title":"Leukemia"},{"key":"1_CR73_1","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood.V86.12.4603.bloodjournal86124603","volume":"86","author":"JW Voncken","year":"1995","unstructured":"Voncken JW, Kaartinen V, Pattengale PK, Germeraad WT, Groffen J, Heisterkamp N (1995) BCR\/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 86:4603\u20134611","journal-title":"Blood"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-01222-8_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T03:21:54Z","timestamp":1739416914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-01222-8_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"ISBN":["9783642012211","9783642012228"],"references-count":73,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-01222-8_1","relation":{},"ISSN":["0080-0015"],"issn-type":[{"value":"0080-0015","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10,7]]},"assertion":[{"value":"7 October 2009","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}